Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides

Ikeda, Yasunori; Charef, Said; Ouidja, Mohand Ouidir; Barbier-Chassefière, Véronique; Siñeriz, Fernando; Duchesnay, Arlette; Narasimprakash, Hemalata; Martelly, Isabelle; Kern, Patrick; Barritault, Denis; Petit, Emmanuel; Papy-García, Dulce

doi:10.1016/j.biomaterials.2010.09.043

Cited by 39 publications

(39 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Glycosaminoglycans contribute to the regulation of this cellular communication 17 ; in particular, heparan sulfates anchor and protect various growth factors and provide structure to the extracellular matrix by linking various structural proteins such as collagen, elastin, and fibronectin. 17,22 Heparan sulfate mimetic polymers, also named RGTAs, were engineered to replace the heparan sulfates bound to matrix proteins and growth factors in damaged cornea. RGTA is expected to bind to "heparan binding sites" on matrix proteins that become available as glycosaminoglycans are degraded by glycanases activated during the inflammation.…”

Section: Discussionmentioning

confidence: 99%

A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus

Gümüş¹,

Guerra²,

Marques³

et al. 2017

J Refract Surg

Self Cite

View full text Add to dashboard Cite

PURPOSE: To investigate the hypothesis that a new matrix therapy agent (ReGeneraTing Agent, [RGTA]) would speed up the corneal reepithelialization, improve stromal healing, and reduce ocular symptoms after epi-off corneal cross-linking (CXL). METHODS: Sixty eyes of 60 patients with progressive keratoconus were enrolled in the study. Epi-off accelerated CXL was performed in all patients. Sixty eyes were randomized into two groups according to use of RGTA eye drops prior to contact lens fitting at the end. Identical medical agents were started postoperatively for the two groups. All participants were monitored on 3 consecutive days after the CXL. Ocular pain, burning, stinging, tearing, photophobia, conjunctival hyperemia, and corneal healing status were evaluated. RESULTS: By day 2, 25 eyes (83.3%) with RGTA revealed complete healing compared to 4 eyes (13.3%) that revealed complete healing in the control group ( P < .001). All eyes had complete corneal epithelial defect closure by day 3 in both groups. Ocular pain scores were lower in the RGTA group on days 0, 1, and 2 (all P < .05). Burning scores were lower on days 1 and 2; stinging scores on days 2 and 3; tearing scores on days 2 and 3; and photophobia on days 1 and 2 ( P < .05) in the RGTA group compared to the control group. CONCLUSIONS: RGTA ophthalmic solution facilitates corneal healing by reconstructing the extracellular matrix in the wound area, leading to an earlier relief of symptoms for patients. [ J Refract Surg. 2017;33(3):163–170.]

show abstract

Section: Discussionmentioning

confidence: 99%

A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus

Gümüş¹,

Guerra²,

Marques³

et al. 2017

J Refract Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…ReGeneraTing Agents (RGTAs) are synthetic heparan sulfate mimics, resistant to glycanase digestion (Figure 2) (Barbier-Chassefiere, Garcia-Filipe et al 2009;Ikeda, Charef et al 2011). Fig.…”

Section: Structure Of Rgtamentioning

confidence: 99%

“…RGTA OTR4120 is prepared as a 85kD molecular weight fraction from T40 dextran by carboxymethylation and O-sulfonation (Barbier-Chassefiere, 2009;Ikeda, Charef et al 2011). RGTA OTR4120 was proven completely resistant to digestion with multiple endoglycanases: heparanase, chondroitinase, hyaluronidase, dextranase (Table 4) (Ikeda, Charef et al 2011).…”

Section: Synthesis Dosing and Timingmentioning

confidence: 99%

“…RGTA OTR4120 was proven completely resistant to digestion with multiple endoglycanases: heparanase, chondroitinase, hyaluronidase, dextranase (Table 4) (Ikeda, Charef et al 2011).…”

Section: Synthesis Dosing and Timingmentioning

confidence: 99%

“…Research to reduce the complexity of the molecule, to facilitate its synthesis and to increase its effectiveness, is ongoing (Ikeda, Charef et al 2011). Also oral administration, as a patient friendly means of administration with a RGTA OTR4120 delivery to the side of injury via (micro)circulation, are tested (Charef, Papy-Garcia et al 2010) …”

Section: Future Perspectivesmentioning

confidence: 99%

See 2 more Smart Citations

Heparan Sulfate Proteoglycan Mimetics Promote Tissue Regeneration: An Overview

Neck¹,

Tuk²,

Barritault³

et al. 2012

Tissue Regeneration - From Basic Biology to Clinical Application

Self Cite

View full text Add to dashboard Cite

Engineered Sulfated Polysaccharides for Biomedical Applications

Arlov

Rütsche

Korayem

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Sulfated polysaccharides are ubiquitous in living systems and have central roles in biological functions such as organism development, cell proliferation and differentiation, cellular communication, tissue homeostasis, and host defense. Engineered sulfated polysaccharides (ESPs) are structural derivatives not found in nature but generated through chemical and enzymatic modification of natural polysaccharides, as well as chemically synthesized oligo‐ and polysaccharides. ESPs exhibit novel and augmented biological properties compared with their unmodified counterparts, mainly through facilitating interactions with other macromolecules. These interactions are closely linked to their sulfation patterns and backbone structures, providing a means to fine‐tune biological properties and characterize structural–functional relationships by employing well‐characterized polysaccharides and strategies for regioselective modification. The following review provides a comprehensive overview of the synthesis and characterization of ESPs and of their biological properties. Through the pioneering research presented here, key emerging application areas for ESPs, which can lead to novel breakthroughs in biomedical research and clinical treatments, are highlighted.

show abstract

Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides

Cited by 39 publications

References 29 publications

A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus

A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus

Heparan Sulfate Proteoglycan Mimetics Promote Tissue Regeneration: An Overview

Engineered Sulfated Polysaccharides for Biomedical Applications

Contact Info

Product

Resources

About